Published in Stat Med on September 20, 2009
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Stochastic relaxation, gibbs distributions, and the bayesian restoration of images. IEEE Trans Pattern Anal Mach Intell (1984) 29.05
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Pancreatic cancer. Lancet (2004) 11.63
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
The Bayesian revolution in genetics. Nat Rev Genet (2004) 4.50
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Realizing the promise of genomics in biomedical research. JAMA (2005) 1.92
Pharmacogenomics: bench to bedside. Nat Rev Drug Discov (2004) 1.63
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics (2008) 1.26
Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics (2005) 1.13
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics (2003) 1.12
The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. Pharmacogenomics (2002) 1.08
Mycophenolates in transplantation. Clin Transplant (2004) 0.98
Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet (2005) 0.97
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell (2009) 4.48
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res (2003) 3.39
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature (2011) 3.10
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res (2008) 2.58
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am J Hum Genet (2002) 2.51
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev (2007) 2.11
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Methods to impute missing genotypes for population data. Hum Genet (2007) 1.98
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res (2010) 1.87
Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol (2002) 1.86
Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet (2006) 1.76
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One (2009) 1.75
Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clin Cancer Res (2007) 1.75
Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem (2006) 1.74
Human aromatase: gene resequencing and functional genomics. Cancer Res (2005) 1.71
Power comparisons between similarity-based multilocus association methods, logistic regression, and score tests for haplotypes. Genet Epidemiol (2009) 1.68
DNA methylation contributes to natural human variation. Genome Res (2013) 1.66
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer (2004) 1.64
Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol (2003) 1.63
Pharmacogenomics: bench to bedside. Nat Rev Drug Discov (2004) 1.63
Where are the prostate cancer genes?--A summary of eight genome wide searches. Prostate (2003) 1.60
Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma (2008) 1.60
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.57
Next generation analytic tools for large scale genetic epidemiology studies of complex diseases. Genet Epidemiol (2011) 1.47
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Sumoylation of MDC1 is important for proper DNA damage response. EMBO J (2012) 1.44
Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet (2002) 1.41
Sequential haplotype scan methods for association analysis. Genet Epidemiol (2007) 1.38
Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet (2006) 1.37
Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res (2011) 1.32
Current results of open revascularization for chronic mesenteric ischemia: a standard for comparison. J Vasc Surg (2002) 1.29
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Strong evidence of a genetic determinant for mammographic density, a major risk factor for breast cancer. Cancer Res (2007) 1.26
A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat (2006) 1.25
Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics (2005) 1.23
Familial aggregation of Parkinson's disease: The Mayo Clinic family study. Ann Neurol (2004) 1.21
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet (2007) 1.20
Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metab Dispos (2006) 1.17
The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther (2005) 1.17
Polymorphisms in mitochondrial genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.17
Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate (2006) 1.16
Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study. Ann Neurol (2006) 1.16
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res (2010) 1.14
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res (2012) 1.13
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer (2003) 1.11
Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. Prostate (2003) 1.11
Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics (2006) 1.10
Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. Hum Genet (2007) 1.10
Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol (2004) 1.10
Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res (2008) 1.09
The Mayo Clinic family study of Parkinson's disease: study design, instruments, and sample characteristics. Neuroepidemiology (2005) 1.08
Utilizing genotype imputation for the augmentation of sequence data. PLoS One (2010) 1.06
Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization. Mol Genet Metab (2008) 1.05
Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Arch Neurol (2007) 1.05
Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev (2010) 1.04
Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res (2008) 1.02
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol (2013) 1.02
Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther (2004) 1.01
Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.01
Use of the gamma method for self-contained gene-set analysis of SNP data. Eur J Hum Genet (2011) 1.01
The kinship2 R package for pedigree data. Hum Hered (2014) 1.00
Increased risk of essential tremor in first-degree relatives of patients with Parkinson's disease. Mov Disord (2007) 1.00
Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J Infect Dis (2002) 0.98
Barrett's esophagus: prevalence in symptomatic relatives. Am J Gastroenterol (2002) 0.98
Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem (2005) 0.98
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res (2011) 0.98
The association of class I HLA alleles and antibody levels after a single dose of measles vaccine. Hum Immunol (2003) 0.97
Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer (2003) 0.96
A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomarkers Prev (2007) 0.96
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet (2015) 0.95
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol (2014) 0.94
Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet (2009) 0.94
Genotype determination for polymorphisms in linkage disequilibrium. BMC Bioinformatics (2009) 0.94
Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. BMC Cancer (2012) 0.94
Early abdominal closure with mesh reduces multiple organ failure after ruptured abdominal aortic aneurysm repair: guidelines from a 10-year case-control study. J Vasc Surg (2002) 0.94
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet (2013) 0.93
Trees Assembling Mann-Whitney approach for detecting genome-wide joint association among low-marginal-effect loci. Genet Epidemiol (2012) 0.93
No association of germline alteration of MSR1 with prostate cancer risk. Nat Genet (2003) 0.93
Genetic association studies of copy-number variation: should assignment of copy number states precede testing? PLoS One (2012) 0.93
Emerging role of FKBP51 in AKT kinase/protein kinase B signaling. Cell Cycle (2010) 0.93